Young Living Essential Oils Corporate – FDA Warning Letter, Jun 10, 2022

The FDA issued a Warning Letter to Young Living on June 10, 2022, following a May 2022 review of their website and consultant social media accounts. The FDA determined that Young Living's "Essential Oil," "Vitality," "Ningxia," and "Nature's Ultra CBD" products are marketed with claims that classify them as drugs under the Federal Food, Drug, and Cosmetic Act.

The letter cites numerous examples of therapeutic claims made by Young Living consultants on various platforms, including treating conditions such as urinary tract infections, yeast infections, kidney stones, acne, allergies, inflammation, arthritis, asthma, heartburn, stomach upset, high body temperatures, high blood pressure, high cholesterol, cancer, addiction, Alzheimer's, anxiety, chronic pain, depression, diabetes, drug withdrawal, epilepsy, glaucoma, insomnia, and Parkinson's disease.

These products are deemed "unapproved new drugs" because there are no adequate and well-controlled clinical studies supporting their general recognition as safe and effective for the claimed uses, and no FDA-approved applications are in effect for them. Marketing these products violates sections 505(a) and 301(d) of the Act.

Furthermore, the products are "misbranded drugs" under section 502(f)(1) of the Act because their labeling lacks adequate directions for use by a layperson for conditions requiring professional medical supervision. As these products are intended to